Treating Type 1 Diabetes Mellitus with a Rapid-Acting Analog Insulin Regimen vs. Regular Human Insulin in Germany: A Long-Term Cost-Effectiveness Evaluation. New application of the PRIME diabetes model.
Assessing the economic value of maintained improvements in Type 1 diabetes management, in terms of HbA1c, weight and hypoglycaemic event incidence. BMI and hypoglycaemia should be key considerations when assessing the value of Type 1 diabetes technologies.
Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. Diabetes Res Clin Pract. 2017 Aug;130:24-33.
The cost-effectiveness of dulaglutide versus insulin glargine for the treatment of type 2 diabetes mellitus in Japan The analysis suggests that dulaglutide 0.75 mg may be a cost-effective treatment alternative to insulin glargine for patients with T2DM in Japan.
The Cost Of Intensive Behavioral Counseling For Prediabetes Patients with CVD Risks? CDC-RTI Diabetes model used to evaluate a U.S. Preventive Services Task Force (USPSTF) recommendation for behavioral counseling interventions for overweight or obese adults. Shows it is cost-effective in a US health care setting.
Incremental cost-effectiveness of screening and laser treatment for diabetic retinopathy and macular edema in Malawi Annual photographic screening of diabetic patients attending medical diabetes clinics in Malawi appears to be cost-effective in terms of QALYs gained.
Projecting diabetes prevalence among Mexicans aged 50 years and older: the Future Elderly Model-Mexico (FEM-Mexico) A simulation study using longitudinal data from the Mexican Health and Aging Study to simulate interventions that could reduce diabetes incidence.
Economic evaluation of chronic disease self-management for people with diabetes: a systematic review Self-management support education programmes may be cost-effective. Poor quality of many of the studies undermines the evidence base regarding the economic efficiency of self-management support interventions for people with diabetes.
Health state utilities associated with attributes of weekly injection devices for treatment of type 2 diabetes. BMC Health Services Research 201717:774. Examines the feasibility of using the TTO method to quantify preferences among injection treatment processes.
Health-related quality of life and health preference of Chinese patients with diabetes mellitus managed in primary care and secondary care setting: decrements associated with individual complication and number of complications. Health Qual Life Outcomes. 2017 Jun 13;15(1):125.
Cost-effectiveness analysis of IDegLira versus basal-bolus insulin for patients with type 2 diabetes in the Slovak health system Another application of the IMS Core diabetes model.
Cost-effectiveness of gastric band surgery for overweight but not obese adults with type 2 diabetes in the U.S. UKPDS Outcomes Model used alongside an RCT to show that gastric band surgery is likely to be cost-effective for overweight people with type 2 diabetes.
Decision modelling for the evaluation of diabetes outcomes A review (in Russian) of available recommendations, relevant methods and mathematical approaches to decision modelling in DM.
Christmas Study Makes News Across the Globe. Do simulation models need to take account when cardiac events occur?
Validation and recalibration of the Framingham cardiovascular disease risk models in an Australian Indigenous cohort First step to building a diabetes simulation model for Indigenous Australians. More
Validation of a Cardiovascular Disease Policy Microsimulation Model Using Both Survival and Receiver Operating Characteristic Curves An approach to validation which could be the subject of a future Mt Hood Challenge
Prostheses Benefit Setting Framework A discussion paper to examine ways to set benefits for prostheses and medical devices such as insulin pumps in Australia.
Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM) ECHO-T2DM passes some validation stress tests.
Projected long-term outcomes in patients with type 1 diabetes treated with fast-acting insulin aspart vs conventional insulin aspart in the UK setting Assesses the impact of faster aspart vs insulin aspart on long-term clinical outcomes and costs for patients with type 1 diabetes mellitus (T1DM) in the UK setting.
The Prime Diabetes model: Novel Methods for Estimating Long-Term Clinical and Cost Outcomes in Type 1 Diabetes Mellitus A new Type 1 diabetes model.
How Consistent is the Relationship between Improved Glucose Control and Modelled Health Outcomes for People with Type 2 Diabetes Mellitus? a Systematic Review Using regression analysis to compare model inputs and outputs.
The place of DPP-4 inhibitors in the treatment algorithm of diabetes type 2: a systematic review of cost-effectiveness studies Provides a review of recent cost-effectiveness studies of DPP-4 inhibitors as well as recent studies comparing them with GLP-1 receptor agonists and insulin glargine.
Incremental Costs and Cost-Effectiveness of Intensive Treatment in Individuals with Type 2 Diabetes Detected by Screening in the ADDITION-UK Trial: An Update with Empirical Trial–Based Cost Data Application of the UKPDS Outcomes Model. Overall conclusion is that the incremental costs of intensive treatment as delivered in the ADDITION-Cambridge trial were lower than expected.
Life Expectancy Predictions for Older Diabetic Patients as Estimated by Physicians and a Prognostic Model The Chicago group show that clinicians AND simulation models produce more accurate forecasts of life expectancy.
A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data. Current practice in HE model validation can be improved by using an alternative method. Also see Assessment of the Validation Status of Health-Economic decision models (AdViSHE) website.
Evaluation of the long-term cost-effectiveness of liraglutide vs lixisenatide for treatment of type 2 diabetes mellitus in the UK setting CORE diabetes model used to evaluate different therapy options for people with Type 2 diabetes.
Why Do Health Economists Promote Technology Adoption Rather Than the Search for Efficiency? A Proposal for a Change in Our Approach to Economic Evaluation in Health Care Should diabetes simulation models be focusing on identifying low value care as well as evaluating new technologies?
Benefits, Challenges and Potential Strategies of Open Source Health Economic Models Is it time for more diabetes models to become open source?